Trial Profile
A Randomized, Double-Masked, Multi-Center Trial of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Intravitreal Injections of Pegaptanib Sodium (Anti-Vegf Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative Age-Related Macular Degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 22 Jun 2014
Price :
$35
*
At a glance
- Drugs Pegaptanib (Primary)
- Indications Wet age-related macular degeneration
- Focus Pharmacokinetics
- Sponsors Eyetech Pharmaceuticals
- 22 Jun 2014 New trial record
- 02 May 2006